AU2007296899B2 - Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma - Google Patents

Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma Download PDF

Info

Publication number
AU2007296899B2
AU2007296899B2 AU2007296899A AU2007296899A AU2007296899B2 AU 2007296899 B2 AU2007296899 B2 AU 2007296899B2 AU 2007296899 A AU2007296899 A AU 2007296899A AU 2007296899 A AU2007296899 A AU 2007296899A AU 2007296899 B2 AU2007296899 B2 AU 2007296899B2
Authority
AU
Australia
Prior art keywords
antibody
fragment
afra
fab
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2007296899A
Other languages
English (en)
Other versions
AU2007296899A1 (en
Inventor
Silvana Canevari
Margherita Cattozzo
Cioccio Vito Di
Mariangela Figini
Franck Martin
Giovanni Maurizi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Accelerator Applications SA
Istituto Nazionale per lo Studio e la Cura die Tumori
Original Assignee
Advanced Accelerator Applications SA
Istituto Nazionale per lo Studio e la Cura die Tumori
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Accelerator Applications SA, Istituto Nazionale per lo Studio e la Cura die Tumori filed Critical Advanced Accelerator Applications SA
Publication of AU2007296899A1 publication Critical patent/AU2007296899A1/en
Assigned to ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI, DOMPE' S.P.A. reassignment ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI Request for Assignment Assignors: DOMPE PHA.R.MA S.P.A., ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI
Assigned to ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI, ADVANCED ACCELERATOR APPLICATIONS SA reassignment ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI Alteration of Name(s) of Applicant(s) under S113 Assignors: DOMPE' S.P.A., ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI
Application granted granted Critical
Publication of AU2007296899B2 publication Critical patent/AU2007296899B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Reproductive Health (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2007296899A 2006-09-15 2007-09-12 Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma Active AU2007296899B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06019399.2 2006-09-15
EP06019399A EP1900752A1 (en) 2006-09-15 2006-09-15 Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
PCT/EP2007/007944 WO2008031577A1 (en) 2006-09-15 2007-09-12 Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma

Publications (2)

Publication Number Publication Date
AU2007296899A1 AU2007296899A1 (en) 2008-03-20
AU2007296899B2 true AU2007296899B2 (en) 2012-09-13

Family

ID=37737768

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007296899A Active AU2007296899B2 (en) 2006-09-15 2007-09-12 Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma

Country Status (14)

Country Link
US (1) US8388972B2 (https=)
EP (2) EP1900752A1 (https=)
JP (1) JP5513114B2 (https=)
KR (1) KR101497045B1 (https=)
AU (1) AU2007296899B2 (https=)
BR (1) BRPI0716811B8 (https=)
CA (1) CA2662005C (https=)
ES (1) ES2644423T3 (https=)
IL (1) IL197300A (https=)
MX (1) MX2009002711A (https=)
NZ (1) NZ575093A (https=)
RU (1) RU2464277C2 (https=)
WO (1) WO2008031577A1 (https=)
ZA (1) ZA200901328B (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2556027C (en) 2004-02-12 2015-11-24 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
EP2172487A1 (en) 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
CN103037900B (zh) * 2010-02-24 2016-04-06 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
WO2012033987A2 (en) 2010-09-09 2012-03-15 Purdue Research Foundation Anti-human folate receptor beta antibodies and methods of use
AU2011323124C1 (en) * 2010-11-05 2016-09-22 Eisai Inc. Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
US9402865B2 (en) 2011-01-18 2016-08-02 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
US20140010756A1 (en) 2011-03-18 2014-01-09 Kagoshima University Composition for treatment and diagnosis of pancreatic cancer
IL281714B2 (en) * 2011-04-01 2023-11-01 Immunogen Inc Methods for increasing the effectiveness of FOLR1 cancer therapy
PL2731972T3 (pl) * 2011-07-15 2018-06-29 Eisai R&D Management Co., Ltd. Przeciwciała skierowane przeciwko receptorowi folianowemu alfa i ich zastosowania
BR112014004168A2 (pt) * 2011-08-23 2017-12-12 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, célula hospedeira procariótica ou eucariótica, método de produção de anticorpo e invenção
EP2822386B1 (en) * 2012-02-29 2021-05-05 Purdue Research Foundation Folate receptor alpha binding ligands
HUE049693T2 (hu) * 2012-08-31 2020-10-28 Immunogen Inc Diagnosztikai ASSAY-k és készletek a folát receptor 1 kimutatására
US9598489B2 (en) 2012-10-05 2017-03-21 The Trustees Of The Univeristy Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
EP2934532B1 (en) 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
AU2014312086B2 (en) * 2013-08-30 2020-03-12 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
IL298044B2 (en) * 2013-10-08 2024-11-01 Immunogen Inc Dosing regimens of anti-FOLR1 immunoconjugate
KR101646577B1 (ko) * 2014-08-14 2016-08-09 원광대학교산학협력단 엽산수용체 표적용 화합물 또는 이의 약학적으로 허용가능한 염과, 이를 유효성분으로 포함하는 암 예방, 진단 또는 치료용 조성물
RS61010B1 (sr) 2014-11-20 2020-11-30 Hoffmann La Roche Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3
DK3221355T3 (da) 2014-11-20 2020-12-07 Hoffmann La Roche Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler CD3 og folatreceptor 1 (FolR1) samt PD-1-aksebindende antagonister
SI3221357T1 (sl) 2014-11-20 2020-09-30 F. Hoffmann-La Roche Ag Pogoste lahke verige in načini uporabe
AU2016323968B2 (en) 2015-09-17 2023-07-06 Immunogen, Inc. Therapeutic combinations comprising anti-FOLR1 immunoconjugates
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物
CN120939250A (zh) 2016-08-12 2025-11-14 L.E.A.F.控股集团公司 聚谷氨酸化抗叶酸剂及其用途
WO2018031979A1 (en) 2016-08-12 2018-02-15 L.E.A.F. Holdings Group Llc Alpha and gamma-d polyglutamated antifolates and uses thereof
SG11201907299XA (en) 2017-02-08 2019-09-27 Dragonfly Therapeutics Inc Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
IL268755B2 (en) 2017-02-20 2025-12-01 Dragonfly Therapeutics Inc Proteins that bind her2, nkg2d, and cd16
JP7178355B2 (ja) 2017-02-28 2022-11-25 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための組成物および方法
US20190231690A1 (en) 2017-11-08 2019-08-01 L.E.A.F. Holdings Group Llc Platinum complexes and uses thereof
JP7549303B2 (ja) 2018-01-22 2024-09-11 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞の使用方法
WO2019157123A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
JP7491573B2 (ja) 2018-02-07 2024-05-28 エル．イー．エー．エフ． ホールディングス グループ エルエルシー アルファポリグルタミン酸化メトトレキセートおよびその使用
US12246015B2 (en) 2018-02-07 2025-03-11 L.E.A.F. Holdings Group Llc Alpha polyglutamated raltitrexed and uses thereof
WO2019157129A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
US12239734B2 (en) 2018-02-07 2025-03-04 L.E.A.F. Holdings Group Llc Gamma polyglutamated raltitrexed and uses thereof
EA202091887A1 (ru) 2018-02-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры
DK3749346T3 (da) 2018-02-08 2024-09-09 Dragonfly Therapeutics Inc Antistof variable domænekombinationer rettet mod nkg2d-receptoren
EP3752156A4 (en) 2018-02-14 2021-10-27 L.E.A.F Holdings Group LLC GAMMA-POLYGLUTAMIZED PRALATREXATE AND USES THEREOF
CN111936145A (zh) 2018-02-14 2020-11-13 L.E.A.F.控股集团公司 γ聚谷氨酸化氨甲蝶呤及其用途
WO2019160732A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated aminopterin and uses thereof
EP3752157A4 (en) 2018-02-14 2022-07-06 L.E.A.F Holdings Group LLC GAMMA-POLYGLUTAMATED LOMETREXOLE AND USES THEREOF
WO2019164930A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
CN112105382A (zh) 2018-02-23 2020-12-18 恩多塞特公司 用于car t细胞疗法的顺序方法
CN115925952A (zh) 2018-03-13 2023-04-07 东莞凡恩世生物医药有限公司 抗叶酸受体1抗体及其用途
US12378318B2 (en) 2018-08-08 2025-08-05 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and a tumor-associated antigen
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
WO2020033630A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
WO2020223221A1 (en) 2019-04-29 2020-11-05 Immunogen, Inc. Biparatopic fr-alpha antibodies and immunoconjugates
CA3149914A1 (en) 2019-08-06 2021-02-11 L.E.A.F. Holdings Group Llc Processes of preparing polyglutamated antifolates and uses of their compositions
CN111393528B (zh) * 2020-01-19 2023-01-31 中国药科大学 一种靶向叶酸受体α的单链抗体及其应用
MX2022013944A (es) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
JP2024508894A (ja) 2021-03-03 2024-02-28 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法
CN117700557B (zh) * 2024-02-05 2024-04-30 卡秋(江苏)生物科技有限公司 一种特异性结合叶酸受体α的抗体或抗原结合片段
CN119757601A (zh) * 2025-01-06 2025-04-04 哈尔滨脉图精准技术有限公司 一种用于卵巢癌诊断的代谢标志物组合及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
ES2263984T3 (es) * 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
CA2556027C (en) 2004-02-12 2015-11-24 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
JP5415763B2 (ja) 2005-10-06 2014-02-12 ドムペ・ファ．ル．マ・ソチエタ・ペル・アツィオーニ 新規選択系

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FIGINI M. ET AL: "Panning Phage Antibody Libraries On Cells: Isolation Of Human Fab Fragments Against Ovarian Carcinoma Using Guided Selection" CANCER RESEARCH, vol. 58, no. 5, 1 March 1998, pages 991-996, *

Also Published As

Publication number Publication date
KR101497045B1 (ko) 2015-02-27
ES2644423T3 (es) 2017-11-28
EP2061813B1 (en) 2017-07-19
BRPI0716811A2 (pt) 2013-11-05
MX2009002711A (es) 2009-06-18
RU2009114161A (ru) 2010-10-20
KR20090059114A (ko) 2009-06-10
CA2662005C (en) 2018-01-02
IL197300A0 (en) 2011-08-01
BRPI0716811B1 (pt) 2020-11-24
JP5513114B2 (ja) 2014-06-04
EP1900752A1 (en) 2008-03-19
IL197300A (en) 2016-02-29
NZ575093A (en) 2012-04-27
RU2464277C2 (ru) 2012-10-20
CA2662005A1 (en) 2008-03-20
BRPI0716811B8 (pt) 2021-05-25
US8388972B2 (en) 2013-03-05
EP2061813A1 (en) 2009-05-27
US20100055034A1 (en) 2010-03-04
WO2008031577A1 (en) 2008-03-20
AU2007296899A1 (en) 2008-03-20
JP2010503386A (ja) 2010-02-04
ZA200901328B (en) 2010-05-26
WO2008031577A8 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
AU2007296899B2 (en) Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
CN109963591B (zh) B7h3抗体-药物偶联物及其医药用途
JP6077745B2 (ja) 抗ポドプラニン抗体、及び抗ポドプラニン抗体を含む医薬組成物
US20170158755A1 (en) Anti-laminin4 antibodies specific for lg1-3
US20250011427A1 (en) Anti-cd3 antibodies with cross-reactivity to human and cynomolgus proteins
CA3203257A1 (en) Anti-b7-h3 antibody and uses thereof
TW202442681A (zh) 抗ror1抗體及其藥物偶聯物
US20240417469A1 (en) Cd3-targeting t-cell engagers with improved therapeutic index
KR20250042144A (ko) Itga2를 표적으로 하는 항체 및 이를 포함하는 항체-약물 접합체(antibody targeting itga2 and antibody-drug conjugate comprising the same)
JP2025520692A (ja) 抗ｓｌｃ３４ａ２モノクローナル抗体およびその使用
US20240026004A1 (en) ANTI-PD-L1/TGF-ß BIFUNCTIONAL ANTIBODY AND USE THEREOF
WO2025131054A1 (en) Antibody drug conjugates targeting to b7-h3 and egfr and the use thereof
WO2025195495A1 (zh) 一种放射性核素偶联物及其制备方法和用途
HK40110049A (zh) 对人和食蟹猴蛋白具有交叉反应性的抗cd3抗体
CN120025446A (zh) 结合分子及抗体药物偶联物和用途
KR20250174736A (ko) L1cam을 표적화하는 항체 및 이의 용도
TW202539735A (zh) 一種包含特異性結合ｄｌｌ３和ｃｄ３的雙特異性抗體的醫藥組成物
CN117402255A (zh) 抗人pd-l1和人ox40的双特异抗体及其应用
HK40108102A (zh) 具有改善的治疗指数的靶向cd3的t细胞衔接器
HK40120912A (zh) 结合分子及抗体药物偶联物和用途
CN121335923A (zh) Ceacam1靶向抗体及其用途
BR112018005837B1 (pt) Anticorpo anti-mesotelina, ácido nucleico, vetor, célula hospedeira, método de preparação do anticorpo e composição farmacêutica

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUM

Free format text: FORMER APPLICANT(S): DOMPE PHA.R.MA S.P.A.; ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI

FGA Letters patent sealed or granted (standard patent)